PD-1 is expressed on the surface of T cells, B cells, and other immune cells. When PD-1 binds to its ligands, PD-L1 or PD-L2, it transmits an inhibitory signal that reduces T cell activity and promotes immune tolerance. This pathway is often exploited by cancer cells to evade immune detection, making PD-1 and its ligands critical targets in cancer immunotherapy.
